- Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
-
Non-alcoholic steatohepatitis (NASH) presents as an epidemic chronic liver disease that is closely associated with metabolic disorders and involves hepatic steatosis, inflammation, and fibrosis as key factors. Despite the enormous global prevalence of NASH, effective pharmacological interventions are lacking. Based on the hypothesis that the multifactorial condition NASH may benefit from combined multiple modes of action for enhanced therapeutic efficacy, we have previously developed dual FXR activators/sEH inhibitors (FXRa/sEHi) and observed remarkable antifibrotic effects upon their use in rodent NASH models. However, these first-generation FXRa/sEHi were characterized by moderate metabolic stability and short in vivo half-life. Aiming to overcome these pharmacokinetic drawbacks, we have systematically studied the structure-activity and structure-stability relationships of the chemotype and obtained second-generation FXRa/sEHi with improved pharmacokinetic parameters. With high plasma exposure, a half-life greater than 5 h, and similar dual potency on the intended targets, 13 presents as a substantially optimized FXRa/sEHi for late-stage preclinical development.
- Helmst?dter, Moritz,Kaiser, Astrid,Brunst, Steffen,Schmidt, Jurema,Ronchetti, Riccardo,Weizel, Lilia,Proschak, Ewgenij,Merk, Daniel
-
supporting information
p. 9525 - 9536
(2021/07/20)
-
- MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
-
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
- -
-
Paragraph 0270; 0272
(2015/11/25)
-
- MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
-
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
- -
-
Paragraph 00167; 00169
(2013/06/05)
-
- Antithrombotic agents
-
This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
- -
-
-
- 1,2-Dibenzamidobenzene inhibitors of human factor Xa
-
High-throughput screening of a combinatorial library of diamidophenols yielded lead compounds with the ability to inhibit human factor Xa (fXa) at micromolar concentrations (e.g. compound 4, fXa apparent K(ass) = 0.64 x 106 L/mol). SAR studies in this novel structural series of fXa inhibitors showed that the phenolic hydroxyl group was not essential for activity. The best activity was found in substituted 1,2-dibenzamidobenzenes in which the phenyl group of one benzoyl group (A-ring) was substituted in the 4-position with relatively small lipophilic or polarizable groups such as methoxy, vinyl, or chloro and the phenyl group of the other benzoyl group (B-ring) was substituted in the 4-position with larger lipophilic groups such as tertbutyl or dimethylamino. The central phenyl ring (C-ring) tolerated a wide variety of substituents, but methoxy, methanesulfonamido, hydroxyl, and carboxyl substitution produced slightly higher levels of activity than other substituents when present in combination with favorable B-ring substitution. Methylation of the amide nitrogen atoms was found to greatly decrease activity. Compound 12 is the highest affinity fXa inhibitor in this group of compounds, having fXa apparent K(ass) = 25.5 x 106 L/mol, about 40x more active than the original lead. This lead series does not show potent inhibition of human thrombin. A model for the binding of these ligands to the fXa active site is proposed. The model is consistent with the observed SAR and can serve to guide future SAR studies.
- Herron, David K.,Goodson Jr., Theodore,Wiley, Michael R.,Weir, Leonard C.,Kyle, Jeffrey A.,Yee, Ying K.,Tebbe, Ann Louise,Tinsley, Jennifer M.,Mendel, David,Masters, John J.,Franciskovich, Jeffry B.,Sawyer, J. Scott,Beight, Douglas W.,Ratz, Andrew M.,Milot, Guy,Hall, Steven E.,Klimkowski, Valentine J.,Wikel, James H.,Eastwood, Brian J.,Towner, Richard D.,Gifford-Moore, Donetta S.,Craft, Trelia J.,Smith, Gerald F.
-
p. 859 - 872
(2007/10/03)
-